Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.
Scorpion, which focuses on “precision medicine” for cancer, said it has completed a $162 million funding round, bringing the biotech’s total venture haul to about $270 million. It’s a large amount for a new company that so far has kept much of its work under wraps, and a sign that the region’s early-stage biotech industry is vibrant, despite the pandemic.
“This will allow us to accelerate nearly all aspects of the business,” said Gary Glick, Scorpion’s chief executive, who pointed out the oversubscribed round brought on 11 new investors.
